The DOI matches its Crossref record; 544 of the 544 references it cites were found in a registry or an index.
The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Research works printed but not linked: 385
- Barge-Caballero, 2017, Prognostic value of the nutritional risk index in heart transplant recipients, Revis Española Cardio (English Edition), 70, 639, 10.1016/j.rec.2017.01.005 · doi:10.1016/j.rec.2017.01.005
- Crawford, 2020, Impact of the new pulmonary hypertension definition on heart transplant outcomes, Chest, 157, 151, 10.1016/j.chest.2019.07.028 · doi:10.1016/j.chest.2019.07.028
- Tsukashita, 2015, Effect of pulmonary vascular resistance before left ventricular assist device implantation on short- and long-term post-transplant survival, J Thorac Cardiovasc Surg, 150, 1352, 10.1016/j.jtcvs.2015.07.012 · doi:10.1016/j.jtcvs.2015.07.012
- Vakil, 2014, Impact of pre-transplant pulmonary hypertension on survival after heart transplantation: a UNOS registry analysis, Int J Cardiol, 176, 595, 10.1016/j.ijcard.2014.08.072 · doi:10.1016/j.ijcard.2014.08.072
- Koulova, 2017, Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation, J Thorac Dis, 9, 2640, 10.21037/jtd.2017.07.24 · doi:10.21037/jtd.2017.07.24
- Nagpal, 2017, Temporary mechanical circulatory support in cardiac critical care: a state of the art review and algorithm for device selection, Can J Cardiol, 33, 110
- Sánchez-Enrique, 2017, Heart transplant and mechanical circulatory support in patients with advanced heart failure, Rev Española Cardiol (English Edition), 70, 371, 10.1016/j.rec.2016.12.036 · doi:10.1016/j.rec.2016.12.036
- Chen, 2018, Prelisting predictions of early postoperative survival in infant heart transplantation using classification and regression tree analysis, Pediatr Transplant, 22, e13105, 10.1111/petr.13105 · doi:10.1111/petr.13105
- Peng, 2019, Risk factors for early and late mortality in pediatric heart transplantation, Pediatr Heart Transplant, 224
- Davies, 2014, Creation of a quantitative score to predict the need for mechanical support in children awaiting heart transplant, Ann Thorac Surg, 98, 675, 10.1016/j.athoracsur.2014.04.087 · doi:10.1016/j.athoracsur.2014.04.087
- Morales, 2019, Third annual pediatric interagency registry for mechanical circulatory support (pedimacs) report: preimplant characteristics and outcomes, Ann Thorac Surg, 107, 993, 10.1016/j.athoracsur.2019.01.038 · doi:10.1016/j.athoracsur.2019.01.038
- Yarlagadda, 2017, Temporary circulatory support in U.S. children awaiting heart transplantation, J Am Coll Cardiol, 70, 2250, 10.1016/j.jacc.2017.08.072 · doi:10.1016/j.jacc.2017.08.072
- Kubak, 2009, Use of hearts transplanted from donors with severe sepsis and infectious deaths, J Heart Lung Transplant, 28, 260, 10.1016/j.healun.2008.11.911 · doi:10.1016/j.healun.2008.11.911
- Wolfe, 2019, Donor-derived infections: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, Clin Transplant, 33
- Ising, 2018, Changing demographics of heart donors: the impact of donor drug intoxication on posttransplant survival, Am J Transplant, 18, 1790, 10.1111/ajt.14726 · doi:10.1111/ajt.14726
- Jacob, 2015, Chronic alcoholic donors in heart transplantation: a mortality meta-analysis, Int J Cardiol, 191, 7, 10.1016/j.ijcard.2015.04.253 · doi:10.1016/j.ijcard.2015.04.253
- Taghavi, 2014, Use of heavy drinking donors in heart transplantation is not associated with worse short- and medium-term mortality, J Heart Lung Transplant, 33, S267, 10.1016/j.healun.2014.01.708 · doi:10.1016/j.healun.2014.01.708
- Warraich, 2017, Trends and outcomes of cardiac transplantation from donors dying of drug intoxication, J Card Fail, 23, S118, 10.1016/j.cardfail.2017.07.346 · doi:10.1016/j.cardfail.2017.07.346
- Martin-Suarez, 2008, Cardiac transplantation from a carbon monoxide intoxicated donor, Transplant Proc, 40, 1563, 10.1016/j.transproceed.2008.03.155 · doi:10.1016/j.transproceed.2008.03.155
- Sezgin, 2008, Successful cardiac transplantation from donor with carbon monoxide intoxication: a case report, Transplant Proc, 40, 324, 10.1016/j.transproceed.2007.11.061 · doi:10.1016/j.transproceed.2007.11.061
- Estevez-Loureiro, 2010, Prevalence of donor-transmitted coronary artery disease and its influence on heart transplant outcomes, Transplant Proc, 42, 2987, 10.1016/j.transproceed.2010.07.088 · doi:10.1016/j.transproceed.2010.07.088
- Kimura, 2018, Impact of coronary artery calcification in the donor heart on transmitted coronary artery disease in heart transplant recipients, Circ J, 82, 3021, 10.1253/circj.CJ-18-0107 · doi:10.1253/circj.cj-18-0107
- Pinto, 2013, Coronary artery bypass graft surgery during heart transplantation, Interactive CardioVascular and Thoracic Surgery, 16, 224, 10.1093/icvts/ivs432 · doi:10.1093/icvts/ivs432
- Patel, 2017, Bioprosthetic aortic valve replacement in a donor heart before orthotopic heart transplantation, Tex Heart Inst J, 44, 135, 10.14503/THIJ-16-5789 · doi:10.14503/thij-16-5789
- Pawale, 2012, Bench mitral valve repair of donor hearts before orthotopic heart transplantation, Circulation: Heart Fail, 5, 96
- Sprengel, 2018, Combined mitral valve repair and heart transplantation, Clin Case Rep, 6, 564, 10.1002/ccr3.1342 · doi:10.1002/ccr3.1342
- Sultan, 2018, Concomitant aortic valve replacement with orthotopic heart transplantation, J Thorac Cardiovasc Surg, 155, e151, 10.1016/j.jtcvs.2017.10.125 · doi:10.1016/j.jtcvs.2017.10.125
- Wever Pinzon, 2011, Impact of donor left ventricular hypertrophy on survival after heart transplant, Am J Transplant, 11, 2755, 10.1111/j.1600-6143.2011.03744.x · doi:10.1111/j.1600-6143.2011.03744.x
- Chen, 2017, Low ejection fraction in donor hearts is not directly associated with increased recipient mortality, J Heart Lung Transplant, 36, 611, 10.1016/j.healun.2017.02.001 · doi:10.1016/j.healun.2017.02.001
- Sibona, 2019, Long-term transplant outcomes of donor hearts with left ventricular dysfunction, J Thorac Cardiovasc Surg, 157, 1865, 10.1016/j.jtcvs.2018.07.115 · doi:10.1016/j.jtcvs.2018.07.115
- Chew, 2019, Outcomes of donation after circulatory death heart transplantation in Australia, J Am Coll Cardiol, 73, 1447, 10.1016/j.jacc.2018.12.067 · doi:10.1016/j.jacc.2018.12.067
- Messer, 2017, Outcome after heart transplantation from donation after circulatory-determined death donors, J Heart Lung Transplant, 36, 1311, 10.1016/j.healun.2017.10.021 · doi:10.1016/j.healun.2017.10.021
- Nyawo, 2008, The effect of a large proximal haemodialysis arterio-venous fistula on weaning off cardiopulmonary bypass: case report, J Cardiothorac Surg, 3, 44, 10.1186/1749-8090-3-44 · doi:10.1186/1749-8090-3-44
- Awad, 2017, Combined heart and kidney transplantation: a 23-year experience, Transplant Proc, 49, 348, 10.1016/j.transproceed.2016.11.040 · doi:10.1016/j.transproceed.2016.11.040
- Chou, 2019, Heart-kidney and heart-liver transplantation provide immunoprotection to the cardiac allograft, Ann Thorac Surg, 108, 458, 10.1016/j.athoracsur.2019.02.012 · doi:10.1016/j.athoracsur.2019.02.012
- Nagpal, 2013, Combined heart and liver transplantation: the cleveland clinic experience, Ann Thorac Surg, 95, 179, 10.1016/j.athoracsur.2012.09.010 · doi:10.1016/j.athoracsur.2012.09.010
- Healy, 2013, Impact of ventricular assist device complications on posttransplant survival: an analysis of the united network of organ sharing database, Ann Thorac Surg, 95, 870, 10.1016/j.athoracsur.2012.10.080 · doi:10.1016/j.athoracsur.2012.10.080
- Healy, 2016, Predictors of 30-day post-transplant mortality in patients bridged to transplantation with continuous-flow left ventricular assist devices—an analysis of the International Society for Heart and Lung Transplantation Transplant Registry, J Heart Lung Transplant, 35, 34, 10.1016/j.healun.2015.07.007 · doi:10.1016/j.healun.2015.07.007
- Bozzetti, 2008, Concomitant pulmonary hypertension and vasoplegia syndrome after heart transplant: a challenging picture, J Cardiothorac Vasc Anesth, 22, 868, 10.1053/j.jvca.2007.11.003 · doi:10.1053/j.jvca.2007.11.003
- Truby, 2018, Incidence and impact of on-cardiopulmonary bypass vasoplegia during heart transplantation, ASAIO J, 64, 43, 10.1097/MAT.0000000000000623 · doi:10.1097/mat.0000000000000623
- Lee, 2016, Prothrombin complex concentrate and methylene blue for treatment of coagulopathy and vasoplegia in a pediatric heart transplant patient, A Case Reports, 6, 127, 10.1213/XAA.0000000000000271 · doi:10.1213/xaa.0000000000000271
- Raza, 2018, Relation of vasoplegia in the absence of primary graft dysfunction to mortality following cardiac transplantation, Am J Cardiol, 122, 1902, 10.1016/j.amjcard.2018.08.035 · doi:10.1016/j.amjcard.2018.08.035
- Zundel, 2016, Use of oral droxidopa to improve arterial pressure and reduce vasoactive drug requirements during persistent vasoplegic syndrome after cardiac transplantation, J Cardiothorac Vasc Anesth, 30, 1624, 10.1053/j.jvca.2015.12.013 · doi:10.1053/j.jvca.2015.12.013
- Kieler-Jensen, 1995, Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside, J Heart Lung Transplant, 14, 436
- McGinn, 2016, A comparison of inhaled nitric oxide versus inhaled epoprostenol for acute pulmonary hypertension following cardiac surgery, Ann Pharmacother, 50, 22, 10.1177/1060028015608865 · doi:10.1177/1060028015608865
- Rao, 2018, Inhaled nitric oxide (iNO) and inhaled epoprostenol (iPGI 2) use in cardiothoracic surgical patients: is there sufficient evidence for evidence-based recommendations?, J Cardiothorac Vasc Anesth, 32, 1452, 10.1053/j.jvca.2017.12.014 · doi:10.1053/j.jvca.2017.12.014
- Torbic, 2013, Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients, J Crit Care, 28, 844, 10.1016/j.jcrc.2013.03.006 · doi:10.1016/j.jcrc.2013.03.006
- Ahmari, 2006, Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter, J Heart Lung Transplant, 25, 53, 10.1016/j.healun.2005.07.017 · doi:10.1016/j.healun.2005.07.017
- Nof, 2013, Catheter ablation of atrial arrhythmias after cardiac transplantation: findings at EP study utility of 3-D mapping and outcomes: catheter ablation of atrial arrhythmias, J Cardiovasc Electrophysiol, 24, 498, 10.1111/jce.12078 · doi:10.1111/jce.12078
- Schumacher, 2011, Postoperative care of the transplanted patient, Curr Cardiol Rev, 7, 110, 10.2174/157340311797484286 · doi:10.2174/157340311797484286
- Holzhauser, 2018, Consequences of retained defibrillator and pacemaker leads after heart transplantation—an underrecognized problem, J Card Fail, 24, 101, 10.1016/j.cardfail.2017.12.012 · doi:10.1016/j.cardfail.2017.12.012
- Albatati, 2020, Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients, Pediatr Res, 87, 892, 10.1038/s41390-019-0523-4 · doi:10.1038/s41390-019-0523-4
- Manlhiot, 2010, Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients, J Heart Lung Transplant, 29, 648, 10.1016/j.healun.2010.01.013 · doi:10.1016/j.healun.2010.01.013
- Schubert, 2008, Relationship of immunosuppression to Epstein–Barr viral load and lymphoproliferative disease in pediatric heart transplant Patients, J Heart Lung Transplant, 27, 100, 10.1016/j.healun.2007.09.027 · doi:10.1016/j.healun.2007.09.027
- Abdala, 2018, Endemic fungal infection recommendations for solid-organ transplant recipients and donors, Transplantation, 102, S52, 10.1097/TP.0000000000002020 · doi:10.1097/tp.0000000000002020
- Grossi, 1993, Pneumocystis carinii pneumonia in heart transplant recipients, Infection, 21, 75, 10.1007/BF01710735 · doi:10.1007/bf01710735
- Hall, 1993, Coccidioidomycosis and heart transplantation, J Heart Lung Transplant, 12, 525
- Hosseini-Moghaddam, 2019, A multicenter case-control study of the effect of acute rejection and cytomegalovirus infection on pneumocystis pneumonia in solid organ transplant recipients, Clin Infect Dis, 68, 1320, 10.1093/cid/ciy682 · doi:10.1093/cid/ciy682
- La Hoz RM, Morris MI. Transplantation tIDCoPotASo, Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients— guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:1-20. · doi:10.1111/ctr.13546
- Ng, 2011, Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients: pediatric outcomes of Pneumocystis jiroveci pneumonia, Pediatr Transplant, 15, 844, 10.1111/j.1399-3046.2011.01589.x · doi:10.1111/j.1399-3046.2011.01589.x
- Saxena, 2018, Invasive fungal disease in pediatric solid organ transplant recipients, J Pediatr Infect Dis Soc, 7, 219, 10.1093/jpids/pix041 · doi:10.1093/jpids/pix041
- Berg, 2017, Mortality risk stratification in fontan patients who underwent heart transplantation, Am J Cardiol, 119, 1675, 10.1016/j.amjcard.2017.02.005 · doi:10.1016/j.amjcard.2017.02.005
- Gokanapudy, 2019, Heart transplantation for the failed fontan, Pediatric heart transplantation, 28
- Schleiger, 2020, Treatment strategies for protein-losing enteropathy in Fontan-palliated patients, Cardiol Young, 30, 698, 10.1017/S1047951120000864 · doi:10.1017/s1047951120000864
- Schumacher, 2019, Fontan-associated protein-losing enteropathy and post‒heart transplant outcomes: a multicenter study, J Heart Lung Transplant, 38, 17, 10.1016/j.healun.2018.09.024 · doi:10.1016/j.healun.2018.09.024
- Dori, 2013, Acute effects of embolizing systemic-to-pulmonary arterial collaterals on blood flow in patients with superior cavopulmonary connections: a pilot study, Circ Cardiovasc Interv, 6, 101, 10.1161/CIRCINTERVENTIONS.112.972265 · doi:10.1161/circinterventions.112.972265
- Krishnan, 2004, Management of aortopulmonary collaterals in children following cardiac transplantation for complex congenital heart disease, J Heart Lung Transplant, 23, 564, 10.1016/S1053-2498(03)00305-X · doi:10.1016/s1053-2498(03)00305-x
- Kobashigawa, 2018, The management of antibodies in heart transplantation: an ISHLT consensus document, J Heart Lung Transplant, 37, 537, 10.1016/j.healun.2018.01.1291 · doi:10.1016/j.healun.2018.01.1291
- Ko, 2016, Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant, J Heart Lung Transplant, 35, 1024, 10.1016/j.healun.2016.05.001 · doi:10.1016/j.healun.2016.05.001
- Reinsmoen, 2016, Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens, J Heart Lung Transplant, 35, 165, 10.1016/j.healun.2015.10.013 · doi:10.1016/j.healun.2015.10.013
- Laing, 2010, Glutaraldehyde treatment of allograft tissue decreases allosensitization after the Norwood procedure, J Thorac Cardiovasc Surg, 139, 1402, 10.1016/j.jtcvs.2009.12.034 · doi:10.1016/j.jtcvs.2009.12.034
- Mahle, 2011, Allosensitization and outcomes in pediatric heart transplantation, J Heart Lung Transplant, 30, 1221, 10.1016/j.healun.2011.06.005 · doi:10.1016/j.healun.2011.06.005
- Meyer, 2005, Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation, Eur J Cardiothorac Surg, 27, 554, 10.1016/j.ejcts.2004.12.033 · doi:10.1016/j.ejcts.2004.12.033
- Patel, 2021, Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients, Am J Transplant, 21, 2479, 10.1111/ajt.16420 · doi:10.1111/ajt.16420
- Foreman, 2004, ABO-incompatible heart transplantation: a perfusion strategy, Perfusion, 19, 69, 10.1191/0267659104pf708oa · doi:10.1191/0267659104pf708oa
- Urschel, 2013, ABO-incompatible heart transplantation in early childhood: an international multicenter study of clinical experiences and limits, J Heart Lung Transplant, 32, 285, 10.1016/j.healun.2012.11.022 · doi:10.1016/j.healun.2012.11.022
- Urschel, 2020, A current era analysis of ABO incompatible listing practice and impact on outcomes in young children requiring heart transplantation, J Heart Lung Transplant, 39, 627, 10.1016/j.healun.2020.02.008 · doi:10.1016/j.healun.2020.02.008
- Profita, 2019, Incidence, predictors, and outcomes after severe primary graft dysfunction in pediatric heart transplant recipients, J Heart Lung Transplant, 38, 601, 10.1016/j.healun.2019.01.1310 · doi:10.1016/j.healun.2019.01.1310
- Simmonds, 2015, Predictors and outcome of extracorporeal life support after pediatric heart transplantation, Ann Thorac Surg, 99, 2166, 10.1016/j.athoracsur.2015.02.047 · doi:10.1016/j.athoracsur.2015.02.047
- Irving, 2015, ABO-incompatible cardiac transplantation in pediatric patients with high isohemagglutinin titers, J Heart Lung Transplant, 34, 1095, 10.1016/j.healun.2015.03.013 · doi:10.1016/j.healun.2015.03.013
- Jeyakanthan, 2012, Donor-specific isohemagglutinins: measuring the unknown: isohemagglutinins: measuring the unknown, Am J Transplant, 12, 803, 10.1111/j.1600-6143.2011.03913.x · doi:10.1111/j.1600-6143.2011.03913.x
- AuBuchon, 2008, Reducing the variation in performance of antibody titrations, Arch Pathol Lab Med, 132, 1194, 10.5858/2008-132-1194-RTVIPO · doi:10.5858/2008-132-1194-rtvipo
- Dean, 2018, Current state of transfusion practices for ABO-incompatible pediatric heart transplant patients in the United States and Canada: PEDIATRIC ABOiHT TRANSFUSION SUPPORT, Transfusion (Paris), 58, 2243, 10.1111/trf.14775 · doi:10.1111/trf.14775
- Robertson, 2018, A novel method for ABO-incompatible heart transplantation, J Heart Lung Transplant, 37, 451, 10.1016/j.healun.2017.05.006 · DOI
- Breuer, 2013, Management of cardiac surgery patients with Heparin-Induced Thrombocytopenia (HIT-II): experience with preoperative plasmaphereses plus intraoperative heparin, Eur Heart J, 34, 10.1093/eurheartj/eht310.P4888 · doi:10.1093/eurheartj/eht310.p4888
- Dalal, 2016, Organ transplantation and drug eluting stents: perioperative challenges, World J Transplant, 6, 620, 10.5500/wjt.v6.i4.620 · doi:10.5500/wjt.v6.i4.620
- Hollis, 2016, Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation, Ann Cardiac Anaesth, 19, 418, 10.4103/0971-9784.185523 · doi:10.4103/0971-9784.185523
- Loforte, 2019, Heart transplant and hepato-renal dysfunction: the model of end-stage liver disease excluding international normalized ratio as a predictor of postoperative outcomes, Transplant Proc, 51, 2962, 10.1016/j.transproceed.2019.07.013 · doi:10.1016/j.transproceed.2019.07.013
- Moretz, 2019, Anticoagulation reversal and risk of thromboembolic events among heart transplant recipients bridged with durable mechanical circulatory support devices, ASAIO J, 65, 649, 10.1097/MAT.0000000000000866 · doi:10.1097/mat.0000000000000866
- Pishko, 2017, Heparin-induced thrombocytopenia in cardiac surgery patients, Semin Thromb Hemost, 43, 691, 10.1055/s-0037-1602664 · doi:10.1055/s-0037-1602664
- Shore-Lesserson, 2018, STS/SCA/AmSECT clinical practice guidelines: anticoagulation during cardiopulmonary bypass, J Extra Corpor Technol, 50, 5, 10.1051/ject/201850005 · doi:10.1051/ject/201850005
- Wanek, 2019, Prothrombin complex concentrates for warfarin reversal before heart transplantation, Ann Thorac Surg, 107, 1409, 10.1016/j.athoracsur.2018.10.032 · doi:10.1016/j.athoracsur.2018.10.032
- Wu, 2018, Impact of prothrombin complex concentrate on blood use, cost, and outcomes in heart transplantation, Ann Thorac Surg, 105, 1152, 10.1016/j.athoracsur.2017.10.044 · doi:10.1016/j.athoracsur.2017.10.044
- Kaushal, 2014, A multicenter study of primary graft failure after infant heart transplantation: impact of extracorporeal membrane oxygenation on outcomes, Pediatr Transplant, 18, 72, 10.1111/petr.12181 · doi:10.1111/petr.12181
- Lima, 2015, Experience of ECMO in primary graft dysfunction after orthotopic heart transplantation, Arq Bras Cardiol, 105, 285
- Su, 2015, Extracorporeal membrane oxygenation support after pediatric orthotopic heart transplantation, Pediatr Transplant, 19, 68, 10.1111/petr.12382 · doi:10.1111/petr.12382
- Colvin, 2015, Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association, Circulation, 131, 1608, 10.1161/CIR.0000000000000093 · DOI · Paper page
- Everitt, 2012, Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant, J Heart Lung Transplant, 31, 686, 10.1016/j.healun.2012.03.009 · doi:10.1016/j.healun.2012.03.009
- Loupy, 2011, Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy, Am J Transplant, 11, 1478, 10.1111/j.1600-6143.2011.03563.x · doi:10.1111/j.1600-6143.2011.03563.x
- Thrush, 2016, A multi-institutional evaluation of antibody-mediated rejection utilizing the Pediatric Heart Transplant Study database: incidence, therapies and outcomes, J Heart Lung Transplant, 35, 1497, 10.1016/j.healun.2016.06.014 · doi:10.1016/j.healun.2016.06.014
- Kfoury, 2016, Mixed cellular and antibody-mediated rejection in heart transplantation: in-depth pathologic and clinical observations, J Heart Lung Transplant, 35, 335, 10.1016/j.healun.2015.10.016 · doi:10.1016/j.healun.2015.10.016
- Crespo-Leiro, 2012, Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II), Transplantation, 94, 1172, 10.1097/TP.0b013e31826e19e2 · doi:10.1097/tp.0b013e31826e19e2
- Lim, 2019, International Society of Heart and Lung Transplantation position statement on the role of right heart catheterization in the management of heart transplant recipients, J Heart Lung Transplant, 38, 235, 10.1016/j.healun.2018.12.009 · doi:10.1016/j.healun.2018.12.009
- Lammers, 2010, Acute rejection after paediatric heart transplantation: far less common and less severe, Transpl Int, 23, 38, 10.1111/j.1432-2277.2009.00941.x · doi:10.1111/j.1432-2277.2009.00941.x
- Zinn, 2017, Impact of age on incidence and prevalence of moderate-to-severe cellular rejection detected by routine surveillance biopsy in pediatric heart transplantation, J Heart Lung Transplant, 36, 451, 10.1016/j.healun.2016.09.017 · doi:10.1016/j.healun.2016.09.017
- Daly, 2012, Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience, J Heart Lung Transplant, 31, 398, 10.1016/j.healun.2011.11.019 · doi:10.1016/j.healun.2011.11.019
- Godown, 2015, Variation in the use of surveillance endomyocardial biopsy among pediatric heart transplant centers over time, Pediatr Transplant, 19, 612, 10.1111/petr.12518 · doi:10.1111/petr.12518
- Zinn, 2018, Impact of routine surveillance biopsy intensity on the diagnosis of moderate to severe cellular rejection and survival after pediatric heart transplantation, Pediatr Transplant, 22, e13131, 10.1111/petr.13131 · doi:10.1111/petr.13131
- Fitzsimons, 2018, Utility of troponin assays for exclusion of acute cellular rejection after heart transplantation: a systematic review, J Heart Lung Transplant, 37, 631, 10.1016/j.healun.2017.12.008 · doi:10.1016/j.healun.2017.12.008
- Patel, 2014, High-sensitivity cardiac troponin I assay to screen for acute rejection in patients with heart transplant, Circ Heart Fail, 7, 463, 10.1161/CIRCHEARTFAILURE.113.000697 · doi:10.1161/circheartfailure.113.000697
- Arnau-Vives, 2004, Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection, J Heart Lung Transplant, 23, 850, 10.1016/j.healun.2003.08.005 · doi:10.1016/j.healun.2003.08.005
- Garrido, 2009, Usefulness of serial monitoring of B-type natriuretic peptide for the detection of acute rejection after heart transplantation, Am J Cardiol, 103, 1149, 10.1016/j.amjcard.2009.01.008 · doi:10.1016/j.amjcard.2009.01.008
- Crespo-Leiro, 2016, Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II, Eur Heart J, 37, 2591, 10.1093/eurheartj/ehv682 · DOI
- Feingold, 2021, Early findings after integration of donor-derived cell-free DNA into clinical care following pediatric heart transplantation, Pediatr Transplant, e14124
- Kobashigawa, 2010, Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes, J Heart Lung Transplant, 29, 504, 10.1016/j.healun.2009.12.015 · doi:10.1016/j.healun.2009.12.015
- Clerkin, 2017, Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation, J Heart Lung Transplant, 36, 540, 10.1016/j.healun.2016.10.016 · doi:10.1016/j.healun.2016.10.016
- Ho, 2011, Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival, Hum Immunol, 72, 5, 10.1016/j.humimm.2010.10.013 · doi:10.1016/j.humimm.2010.10.013
- Irving, 2015, Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation, J Heart Lung Transplant, 34, 1310, 10.1016/j.healun.2015.05.001 · doi:10.1016/j.healun.2015.05.001
- Simsek, 2015, Diagnostic performance of late gadolinium enhancement in the assessment of acute cellular rejection after heart transplantation, Anatol J Cardiol, 16, 113
- Imran, 2019, Native T1 mapping in the diagnosis of cardiac allograft rejection, JACC: Cardiovasc Imaging, 12, 1618
- Feingold, 2017, Diffuse myocardial fibrosis among healthy pediatric heart transplant recipients: correlation of histology, cardiovascular magnetic resonance, and clinical phenotype, Pediatr Transplant, 21, 1, 10.1111/petr.12986 · doi:10.1111/petr.12986
- Bonnemains, 2015, Design of the DRAGET Study: a multicentre controlled diagnostic study to assess the detection of acute rejection in patients with heart transplant by means of T 2 quantification with MRI in comparison to myocardial biopsies, BMJ Open, 5, 10.1136/bmjopen-2015-008963 · doi:10.1136/bmjopen-2015-008963
- Butler, 2015, Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection, J Heart Lung Transplant, 34, 643, 10.1016/j.healun.2014.12.020 · doi:10.1016/j.healun.2014.12.020
- Dolan, 2019, Multiparametric cardiac magnetic resonance imaging can detect acute cardiac allograft rejection after heart transplantation, JACC: Cardiovasc Imaging, 12, 1632
- Evers, 2019, Outcomes of low-intensity biopsy surveillance for rejection in paediatric cardiac transplantation, Cardiol Young, 29, 910, 10.1017/S1047951119001112 · doi:10.1017/s1047951119001112
- Kindel, 2015, Improved detection of cardiac allograft vasculopathy: a multi-institutional analysis of functional parameters in pediatric heart transplant recipients, J Am Coll Cardiol, 66, 547, 10.1016/j.jacc.2015.05.063 · doi:10.1016/j.jacc.2015.05.063
- Mingo-Santos, 2015, Usefulness of two-dimensional strain parameters to diagnose acute rejection after heart transplantation, J Am Soc Echocardiogr, 28, 1149, 10.1016/j.echo.2015.06.005 · doi:10.1016/j.echo.2015.06.005
- Hernandez, 2015, Global left ventricular relaxation: a novel tissue Doppler index of acute rejection in pediatric heart transplantation, J Heart Lung Transplant, 34, 1190, 10.1016/j.healun.2015.03.027 · doi:10.1016/j.healun.2015.03.027
- Schmoeckel, 2005, Successful ABO-incompatible heart transplantation in two infants, Transpl Int, 18, 1210, 10.1111/j.1432-2277.2005.00181.x · doi:10.1111/j.1432-2277.2005.00181.x
- Almond, 2010, Impact of ABO-Incompatible listing on wait-list outcomes among infants listed for heart transplantation in the United States: a propensity analysis, Circulation, 121, 1926, 10.1161/CIRCULATIONAHA.109.885756 · doi:10.1161/circulationaha.109.885756
- Dipchand, 2010, Equivalent outcomes for pediatric heart transplantation recipients: ABO-blood group incompatible versus ABO-compatible, Am J Transplant, 10, 389, 10.1111/j.1600-6143.2009.02934.x · doi:10.1111/j.1600-6143.2009.02934.x
- Henderson, 2012, ABO-incompatible heart transplantation: analysis of the Pediatric Heart Transplant Study (PHTS) database, J Heart Lung Transplant, 31, 173, 10.1016/j.healun.2011.11.013 · doi:10.1016/j.healun.2011.11.013
- Tydén, 2012, Intentional ABO-incompatible heart transplantation: a case report of 2 adult patients, J Heart Lung Transplant, 31, 1307, 10.1016/j.healun.2012.09.011 · doi:10.1016/j.healun.2012.09.011
- Lehmkuhl, 2009, Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in De Novo heart transplant recipients, Transplantation, 88, 115, 10.1097/TP.0b013e3181aacd22 · doi:10.1097/tp.0b013e3181aacd22
- Zuckermann, 2011, Efficacy and safety of low-dose cyclosporine with everolimus and steroids in de novo heart transplant patients: a multicentre, randomized trial, J Transplant, 2011, 1, 10.1155/2011/535983 · doi:10.1155/2011/535983
- Andreassen, 2016, Everolimus initiation with early calcineurin inhibitor withdrawal in De Novo heart transplant recipients: three-year results from the randomized SCHEDULE study: early switch to everolimus after transplant, Am J Transplant, 16, 1238, 10.1111/ajt.13588 · doi:10.1111/ajt.13588
- Zuckermann, 2014, Sirolimus conversion after heart transplant: risk factors for acute rejection and predictors of renal function response: renal function after conversion to sirolimus, Am J Transplant, 14, 2048, 10.1111/ajt.12833 · doi:10.1111/ajt.12833
- West, 2019, Characteristics, risks, and outcomes of post-transplant lymphoproliferative disease >3 years after pediatric heart transplant: a multicenter analysis, Clin Transplant, 33, e13521, 10.1111/ctr.13521 · doi:10.1111/ctr.13521
- Chinnock, 2011, Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients: CNI minimization leads to improved renal function, Pediatr Transplant, 15, 746, 10.1111/j.1399-3046.2011.01566.x · doi:10.1111/j.1399-3046.2011.01566.x
- Asante-Korang, 2017, Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation, Clin Transplant, 31, e13054, 10.1111/ctr.13054 · doi:10.1111/ctr.13054
- Loar, 2013, Calcineurin inhibitor-free immunosuppression in pediatric heart transplantation recipients: sirolimus as a primary immunosuppressive agent, J Heart Lung Transplant, 32, S292, 10.1016/j.healun.2013.01.775 · doi:10.1016/j.healun.2013.01.775
- Schubert, 2014, Initial experience with CNI-free immunosuppression in pediatric heart transplant recipients - anticipating PTLD and chronic renal insufficiency, Thorac Cardiovasc Surg, 62, 10.1055/s-0034-1394000 · doi:10.1055/s-0034-1394000
- Tett, 2011, Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure, Transplant Rev (Orlando), 25, 47, 10.1016/j.trre.2010.06.001 · doi:10.1016/j.trre.2010.06.001
- Kniepeiss, 2011, The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation: CYP3A5 and dosing of tacrolimus and everolimus, Clin Transplant, 25, 146, 10.1111/j.1399-0012.2009.01198.x · doi:10.1111/j.1399-0012.2009.01198.x
- Arora, 2012, Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate, J Heart Lung Transplant, 31, 259, 10.1016/j.healun.2011.12.010 · doi:10.1016/j.healun.2011.12.010
- González-Vílchez, 2013, Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation, Clin Transplant, 27, E649, 10.1111/ctr.12241 · doi:10.1111/ctr.12241
- Rivinius, 2015, Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy, Drug Des Devel Ther, 9, 93
- Schober, 2013, Characteristics of early and late PTLD development in pediatric solid organ transplant recipients, Transplantation, 95, 240, 10.1097/TP.0b013e318277e344 · doi:10.1097/tp.0b013e318277e344
- Webber, 2006, Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study, Lancet North Am Ed, 367, 233, 10.1016/S0140-6736(06)67933-6 · doi:10.1016/s0140-6736(06)67933-6
- Tzani, 2021, Impact of induction therapy on outcomes after heart transplantation, Clin Transplant, 35, 10.1111/ctr.14440 · doi:10.1111/ctr.14440
- Nozohoor, 2020, Induction immunosuppression strategies and long-term outcomes after heart transplantation, Clin Transplant, 34, e13871, 10.1111/ctr.13871 · doi:10.1111/ctr.13871
- Truby, 2020, Impact of induction immunosuppression on post-transplant outcomes of patients bridged with contemporary left ventricular assist devices, ASAIO J, 66, 261, 10.1097/MAT.0000000000001119 · doi:10.1097/mat.0000000000001119
- Amin, 2019, Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era, Clin Transplant, 33, e13651, 10.1111/ctr.13651 · doi:10.1111/ctr.13651
- Castleberry, 2018, Risk stratification to determine the impact of induction therapy on survival, rejection and adverse events after pediatric heart transplant: a multi-institutional study, J Heart Lung Transplant, 37, 458, 10.1016/j.healun.2017.05.010 · doi:10.1016/j.healun.2017.05.010
- Butts, 2017, Effect of induction therapy on graft survival in primary pediatric heart transplantation: a propensity score analysis of the UNOS database, Transplantation, 101, 1228, 10.1097/TP.0000000000001285 · doi:10.1097/tp.0000000000001285
- Carlo, 2019, Comparison of 10-year graft failure rates after induction with basiliximab or anti-thymocyte globulin in pediatric heart transplant recipients—The influence of race, Pediatr Transplant, 23, 1, 10.1111/petr.13366 · doi:10.1111/petr.13366
- Ansari, 2016, Comparison of basiliximab and anti-thymocyte globulin as induction therapy in pediatric heart transplantation: a survival analysis, J Am Heart Assoc, 5, 1, 10.1161/JAHA.115.002790 · doi:10.1161/jaha.115.002790
- Butts, 2018, Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: an analysis of the International Society for Heart and Lung Transplantation database, Pediatr Transplant, 22, 1, 10.1111/petr.13190 · doi:10.1111/petr.13190
- Grundy, 2009, Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation, J Heart Lung Transplant, 28, 1279, 10.1016/j.healun.2009.09.001 · doi:10.1016/j.healun.2009.09.001
- Morrow, 2012, Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients, Transplantation, 93, 319, 10.1097/TP.0b013e31823f7eea · doi:10.1097/tp.0b013e31823f7eea
- Schumacher, 2012, HLA desensitization in pediatric heart transplant candidates: efficacy of rituximab and IVIg, J Heart Lung Transplant, 31, 1041, 10.1016/j.healun.2012.05.009 · doi:10.1016/j.healun.2012.05.009
- Alloway, 2011, Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations, J Heart Lung Transplant, 30, 1003, 10.1016/j.healun.2011.02.008 · doi:10.1016/j.healun.2011.02.008
- Dressman, 1983, Stability of allopurinol and of five antineoplastics in suspension, Am J Health Syst Pharm, 40, 616, 10.1093/ajhp/40.4.616 · doi:10.1093/ajhp/40.4.616
- Elefante, 2006, Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels, Bone Marrow Transplant, 37, 781, 10.1038/sj.bmt.1705320 · doi:10.1038/sj.bmt.1705320
- Jacobson, 1997, Stability of tacrolimus in an extemporaneously compounded oral liquid, Am J Health Syst Pharm, 54, 178, 10.1093/ajhp/54.2.178 · doi:10.1093/ajhp/54.2.178
- Al Sagheer T, Enderby CY. Determining the conversion ratios for oral versus sublingual administration of tacrolimus in solid organ transplant recipients. Clin Transplant 2019;33:1-6. · doi:10.1111/ctr.13727
- Collin, 2010, Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study, Transplant Proc, 42, 4331, 10.1016/j.transproceed.2010.09.126 · doi:10.1016/j.transproceed.2010.09.126
- Doligalski, 2014, Sublingual administration of tacrolimus: current trends and available evidence, Pharmacotherapy, 34, 1209, 10.1002/phar.1492 · doi:10.1002/phar.1492
- Nasiri-Toosi, 2012, Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients, Exp Clin Transplant, 10, 586, 10.6002/ect.2012.0032 · doi:10.6002/ect.2012.0032
- Tsapepas, 2013, Sublingual tacrolimus: a pharmacokinetic evaluation pilot study, Pharmacotherapy, 33, 31, 10.1002/phar.1149 · doi:10.1002/phar.1149
- Watkins, 2012, Use of sublingual tacrolimus in lung transplant recipients, J Heart Lung Transplant, 31, 127, 10.1016/j.healun.2011.10.015 · doi:10.1016/j.healun.2011.10.015
- Reams, 2002, Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis, Am J Respir Med, 1, 91, 10.1007/BF03256598 · doi:10.1007/bf03256598
- Pennington, 2015, Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients, Am J Health Syst Pharm, 72, 277, 10.2146/ajhp140322 · doi:10.2146/ajhp140322
- Abu-Elmagd, 1991, Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation, Transplant Proc, 23, 2767
- Dhungel, 2012, 655 short-term outcomes in heart transplant recipients treated with generic tacrolimus, J Heart Lung Transplant, 31, S226, 10.1016/j.healun.2012.01.669 · doi:10.1016/j.healun.2012.01.669
- Kraeuter, 2013, Conversion to generic cyclosporine A in stable chronic patients after heart transplantation, Drug Des Devel Ther., 7, 1421
- Söderlund, 2015, Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart transplant patients, Clin Transplant, 29, 619, 10.1111/ctr.12564 · doi:10.1111/ctr.12564
- Spence, 2012, evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system, Pharmacotherapy, 32, 981, 10.1002/phar.1130 · doi:10.1002/phar.1130
- Khush, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match, J Heart Lung Transplant, 38, 1056, 10.1016/j.healun.2019.08.004 · DOI · Paper page
- Kiernan, 2019, Measuring alloantibodies: a matter of quantity and quality, Curr Opin Organ Transplant, 24, 20, 10.1097/MOT.0000000000000593 · doi:10.1097/mot.0000000000000593
- Loupy, 2016, Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection, Am J Transplant, 16, 111, 10.1111/ajt.13529 · doi:10.1111/ajt.13529
- Jain, 2019, Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation, Leuk Lymphoma, 60, 110, 10.1080/10428194.2018.1459603 · doi:10.1080/10428194.2018.1459603
- Fishbein, 2012, Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft, Hum Immunol, 73, 1213, 10.1016/j.humimm.2012.07.011 · doi:10.1016/j.humimm.2012.07.011
- Mokshagundam, 2020, Treatment and pattern of resolution of antibody-mediated rejection with hemodynamic compromise resistant to standard therapy after heart transplantation with a positive virtual crossmatch, J Heart Lung Transplant, 39, S458, 10.1016/j.healun.2020.01.299 · doi:10.1016/j.healun.2020.01.299
- Kobashigawa, 2011, Report from a consensus conference on antibody-mediated rejection in heart transplantation, J Heart Lung Transplant, 30, 252, 10.1016/j.healun.2010.11.003 · DOI · Paper page
- Wu, 2009, Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes, J Heart Lung Transplant, 28, 417, 10.1016/j.healun.2009.01.015 · doi:10.1016/j.healun.2009.01.015
- Kfoury, 2019, The impact of asymptomatic antibody-mediated rejection on outcome after heart transplantation, Curr Opin Organ Transplant, 24, 259, 10.1097/MOT.0000000000000640 · doi:10.1097/mot.0000000000000640
- Conway, 2012, Development of donor-specific isohemagglutinins following pediatric abo-incompatible heart transplantation: isohemagglutinins and heart transplant, Am J Transplant, 12, 888, 10.1111/j.1600-6143.2011.03910.x · doi:10.1111/j.1600-6143.2011.03910.x
- Chen, 2019, Donor-specific anti-HLA antibody production following pediatric ABO-incompatible heart transplantation, Pediatr Transplant, 23, e13332, 10.1111/petr.13332 · doi:10.1111/petr.13332
- Peled, 2017, The impact of gender mismatching on early and late outcomes following heart transplantation, ESC Heart Fail, 4, 31, 10.1002/ehf2.12107 · doi:10.1002/ehf2.12107
- Söderlund, 2017, Acute cellular rejection later than one year after heart transplantation: a single-center retrospective study at Skåne University Hospital in Lund 1988-2010, Clin Transplant, 31, e12998, 10.1111/ctr.12998 · doi:10.1111/ctr.12998
- Tran, 2016, Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation, J Heart Lung Transplant, 35, 87, 10.1016/j.healun.2015.08.008 · doi:10.1016/j.healun.2015.08.008
- Coutance, 2015, Late antibody-mediated rejection after heart transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy, J Heart Lung Transplant, 34, 1050, 10.1016/j.healun.2015.03.002 · doi:10.1016/j.healun.2015.03.002
- Loupy, 2011, Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy: very late heart transplant rejection, Am J Transplant, 11, 1478, 10.1111/j.1600-6143.2011.03563.x · doi:10.1111/j.1600-6143.2011.03563.x
- Tible, 2013, Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation, J Heart Lung Transplant, 32, 769, 10.1016/j.healun.2013.05.012 · doi:10.1016/j.healun.2013.05.012
- Fenton, 2018, Comparative study of pediatric coronary allograft vasculopathy between single centers in North America and United Kingdom, Transplant Proc, 50, 3705, 10.1016/j.transproceed.2018.06.022 · doi:10.1016/j.transproceed.2018.06.022
- McGovern, 2019, Optical coherence tomography for the early detection of coronary vascular changes in children and adolescents after cardiac transplantation, JACC: Cardiovascular Imaging, 12, 2492
- Khanna R. Immune monitoring of infectious complications in transplant patients: an important step towards improved clinical management. J Clin Microbiol 2018;56:1-6. · doi:10.1128/jcm.02009-17
- Baran, 2011, A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial, Circ: Heart Fail, 4, 129
- Baughman, 2012, Therapy for sarcoidosis: evidence-based recommendations, Expert Rev Clin Immunol, 8, 95, 10.1586/eci.11.84 · doi:10.1586/eci.11.84
200 of 385 shown
Cited by
Thompson, A., Fleischmann, K. E., Smilowitz, N. R., de las Fuentes, L., Mukherjee, D., Aggarwal, N. R., Ahmad, F. S., Allen, R. B., Altin, S. E., Auerbach, A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001285 · Cited by 365
Saha, D., Dutta, P., & Chakraborty, A. (2025) · Immuno · doi:10.3390/immuno5040045 · Cited by 3
Metadata
- Authors
- Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., Lavee, J., Pouch, S., Patel, J., Michaud, C., Shullo, M. A., Schubert, S., Angelini, A., Carlos, L., Mirabet, S., Patel, J., Pham, M., Urschel, S., Kim, K.-H., Miyamoto, S., Chih, S., Daly, K., Grossi, P., Jennings, D. L., Kim, I.-C., Lim, H. S., Miller, T., Potena, L., Velleca, A., Eisen, H., Bellumkonda, L., Danziger-Isakov, L., Dobbels, F., Harkess, M., Kim, D., Lyster, H., Peled, Y., & Reinhardt, Z.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 42
- Issue
- 5
- Pages
- e1-e141
- ISSN
- 1053-2498 (ISSN-L)
- OpenAlex
- W4313207390
- Cited by
- 645
- References
- 544
- FWCI
- 102.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. https://app.cochat.ai/papers/10.1016/j.healun.2022.10.015
- The paper
- Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., Lavee, J., Pouch, S., Patel, J., Michaud, C., Shullo, M. A., Schubert, S., Angelini, A., Carlos, L., Mirabet, S., . . . Reinhardt, Z. (2023). The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2022.10.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.